What is the appropriate dosing and safety considerations for using Thorazine (chlorpromazine) to treat persistent hiccups in adults?

Thorazine for Hiccups: Dosing and Safety

For intractable hiccups persisting 2-3 days after oral therapy fails, chlorpromazine (Thorazine) 25-50 mg IM is the FDA-approved treatment, with IV administration (25-50 mg diluted in 500-1000 mL saline) reserved for refractory cases requiring close blood pressure monitoring. 1

Dosing Algorithm

Oral Therapy (First-Line)

• Initial approach: Trial oral chlorpromazine for 2-3 days before escalating to parenteral routes 1
• Standard oral dosing not explicitly detailed in FDA labeling for hiccups, but clinical practice typically uses 25-50 mg orally 3-4 times daily

Intramuscular Administration

• Dose: 25-50 mg IM (1-2 mL) 1
• Indication: Hiccups persisting 2-3 days after oral therapy trial
• Injection technique: Deep into upper outer quadrant of buttock, slowly 1
• Patient positioning: Keep patient lying down for at least 30 minutes post-injection due to hypotensive effects 1

Intravenous Administration (Most Severe Cases)

• Dose: 25-50 mg (1-2 mL) diluted in 500-1000 mL saline 1
• Administration: Slow IV infusion with patient flat in bed 1
• Critical requirement: Close blood pressure monitoring throughout infusion 1
• Dilution imperative: NEVER inject undiluted chlorpromazine into vein 1

Pediatric Dosing (6 months-12 years)

• Generally not recommended under 6 months except when potentially lifesaving 1
• Dosing not well-established for hiccups in children; extrapolate from adult data with caution

Evidence Base

Recent systematic review (2026) analyzing 16 studies found chlorpromazine at 10-25 mg (oral and IM) completely resolved hiccups in multiple case reports and series 2. A 2024 case demonstrated rapid resolution within 2 days using 37.5 mg/day divided three times daily 3. The 2016 NCCN Palliative Care Guidelines mention chlorpromazine as an option for intractable hiccups 4, though this is primarily in the context of pediatric behavioral emergencies rather than a primary hiccup guideline.

Critical Safety Considerations

Cardiovascular Risks

• Orthostatic hypotension: Most significant acute risk, particularly with parenteral administration 5
• QTc prolongation: Can precipitate torsades de pointes 5
• Monitoring: Blood pressure must be followed closely, especially during IV infusion 1
• Reserve parenteral routes for bedfast patients or acute cases where patient can remain supine 1

Hematologic Emergency

• Agranulocytosis: Potentially fatal complication requiring immediate recognition 6
• A 2022 case report documented rapid-onset agranulocytosis within less than 1 week of chlorpromazine 25 mg three times daily for hiccups, resulting in fatal aspergillus pneumonia 6
• This represents an unusually accelerated timeline compared to typical weeks-long onset
• Clinical implication: Monitor for signs of infection; consider CBC if treatment extends beyond several days

Neurological Effects

• Extrapyramidal symptoms (EPSEs): Dystonic reactions, akathisia 5
• Sedation: Significant anticholinergic effects 5
• Paradoxical agitation: Can occur, particularly in elderly 5

Special Populations Requiring Dose Reduction

• Elderly patients: Use lower doses (12.5 mg range), titrate gradually 5
• Renal impairment: Use with caution 5
• Hepatic impairment: Use with caution 5

Contraindications and Precautions

• Avoid in patients with severe pulmonary insufficiency, severe liver disease 5
• Do not use subcutaneous injection 1
• Avoid getting solution on hands/clothing due to contact dermatitis risk 1
• Parenteral use may cause local irritation 5

Alternative Considerations

While chlorpromazine is FDA-approved for intractable hiccups, recent evidence suggests olanzapine (2.5-10 mg oral) may be equally effective with potentially better tolerability 2. Other antipsychotics showing efficacy include haloperidol (1-2 mg), risperidone (3 mg), and tetrabenazine (25-150 mg) 2. However, these lack FDA approval for this indication.

A 2026 case report demonstrated successful treatment with pregabalin in a patient refractory to chlorpromazine, baclofen, and gabapentin 7, suggesting gabapentinoids as potential alternatives when antipsychotics fail or are contraindicated.

Common Pitfalls

1. Underdosing: Using insufficient doses or inadequate duration before declaring treatment failure
2. Inadequate monitoring: Failing to monitor blood pressure during IV administration can result in severe hypotension
3. Ignoring infection risk: Not recognizing early signs of agranulocytosis in patients on multi-day therapy
4. Route selection errors: Using IV route when IM would suffice, or injecting undiluted drug intravenously
5. Elderly dosing: Using standard adult doses in frail elderly patients without downward titration